OPKO Health (NASDAQ:OPK) Hits New 12-Month High – Here’s Why

OPKO Health, Inc. (NASDAQ:OPK)’s stock price reached a new 52-week high during trading on Tuesday. The stock traded as high as $1.78 and last traded at $1.7950, with a volume of 273,701 shares changing hands. The stock had previously closed at $1.72.

OPKO Health News Summary

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could strengthen its finances and allow greater focus on biopharmaceutical operations. OPKO Q3 results and business highlights
• Positive Sentiment: OPKO’s reported quarterly loss was $0.05 per share, better than the Zacks consensus estimate of a $0.07 loss, although it remained loss-making. Zacks Q3 results
• Neutral Sentiment: Following the Labcorp transaction, OPKO forecast 2026 continuing-operations revenue of $268 million to $278 million. That outlook reflects a smaller business after the diagnostics divestiture. 2026 revenue outlook
• Negative Sentiment: Quarterly revenue was reported at $65.4 million, far below the FactSet estimate of $136.6 million. The earnings coverage also cited widening biotech losses and a delayed CAR-T timeline, adding uncertainty to the company’s growth prospects. Q3 earnings call highlights

Wall Street Analyst Weigh In

OPK has been the subject of a number of recent analyst reports. Piper Sandler reissued an “overweight” rating and set a $4.00 price target (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. UBS Group set a $4.00 price target on OPKO Health in a research report on Friday, October 16th. Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective on the stock in a research report on Friday, October 16th. Zacks Research upgraded OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, OPKO Health currently has an average rating of “Moderate Buy” and a consensus target price of $3.42.

OPKO Health Trading Up 2.1%

The business has a 50-day moving average price of $1.58 and a 200-day moving average price of $1.35. The firm has a market capitalization of $1.35 billion, a P/E ratio of -19.28 and a beta of 1.52. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $130.83 million during the quarter, compared to analyst estimates of $136.62 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The company’s quarterly revenue was down 56.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.03 earnings per share. Analysts anticipate that OPKO Health, Inc. will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of OPKO Health during the second quarter worth $55,468,000. AWM Investment Company Inc. bought a new stake in shares of OPKO Health during the second quarter worth $3,165,000. Bank of New York Mellon Corp bought a new stake in shares of OPKO Health during the second quarter worth $1,995,000. Bank of America Corp DE raised its holdings in shares of OPKO Health by 80.0% during the first quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company’s stock worth $1,302,000 after acquiring an additional 507,590 shares during the period. Finally, First Trust Advisors LP bought a new stake in OPKO Health in the 1st quarter valued at $570,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.